Medicine guide

Fludeoxyglucose F-18

300 mCi/mL · Injection

Prescription only
Radioactive Diagnostic Agent

Active substance: Fludeoxyglucose F-18
Used in: Everything that fits nowhere else, such as contrast media
Made by: Barbara Ann Karmanos Cancer Hospital
Source: Official label

Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.

At a glance

Quoted from the official label · 2022-11-10

What it is

Radioactive Diagnostic Agent

Used for

For assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing…

Warning

Radiation risks: use smallest dose necessary for imaging ( 5.1 ).

All warnings ↓

Good to know

Prescription only
FDA enforcement reports list no ongoing recall, and none from the last two years, for this product code · checked 2026-10-02

13other products contain Fludeoxyglucose F-18 — compare makers, forms and strengths

Every line above is selected, not written, from the official label. Nothing is reworded. DailyMed

What it is for

Fludeoxyglucose F 18 Injection is indicated for positron emission tomography (PET) imaging in the following settings:

Oncology:
For assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer.
Cardiology:
For the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function in patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging.
Neurology:
For the identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures ( 1 ).
1.1 Oncology For assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer.
1.2 Cardiology For the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function in patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging.
1.3 Neurology For the identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures.

From the official label · 2022-11-10 · DailyMed

How it works

From this product’s own US prescribing label.

F 18 Fludeoxyglucose is a glucose analog that concentrates in cells that rely upon glucose as an energy source, or in cells whose dependence on glucose increases under pathophysiological conditions.
Fludeoxyglucose F 18 is transported through the cell membrane by facilitative glucose transporter proteins and is phosphorylated within the cell to [F 18] FDG-6-phosphate by the enzyme hexokinase.

Half-life0.2–0.3 min

Mostly cleared after≈ 1 minfive half-lives — our arithmetic

How the body breaks it down

Fludeoxyglucose F 18 is transported into cells and phosphorylated to [F 18]-FDG-6-phosphate at a rate proportional to the rate of glucose utilization within that tissue. [F 18]-FDG-6-phosphate presumably is metabolized to 2-deoxy-2-[F 18]fluoro-6-phospho-D-mannose([F 18]FDM-6-phosphate).

How it leaves the body

Fludeoxyglucose F 18 that is not involved in glucose metabolism in any tissue is then excreted in the urine.

Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2022-11-10

Do not take it if

None None

Quoted from the official label, section “Contraindications”.

How to take it

These directions are for this exact strength and form. Another one is different.

Fludeoxyglucose F 18 Injection emits radiation.
Use procedures to minimize radiation exposure.
Calculate the final dose from the end of synthesis (EOS) time using proper radioactive decay factors.
Assay the final dose in a properly calibrated dose calibrator before administration to the patient [ see Description (11.2) ].
Fludeoxyglucose F 18 Injection emits radiation.
Use procedures to minimize radiation exposure.
Screen for blood glucose abnormalities.
In the oncology and neurology settings, instruct patients to fast for 4 to 6 hours prior to the drug's injection.
Consider medical therapy and laboratory testing to assure at least two days of normoglycemia prior to the drug's administration ( 5.2 ).
In the cardiology setting, administration of glucose-containing food or liquids (e.g., 50 to 75 grams) prior to the drug's injection facilitates localization of cardiac ischemia ( 2.3 ).
Aseptically withdraw Fludeoxyglucose F 18 Injection from its container and administer by intravenous injection ( 2 ).
The recommended dose:
for
adults is 5 to 10 mCi (185 to 370 MBq), in all indicated clinical settings ( 2.1 ). for pediatric patients is 2.6 mCi (96.2 MBq) in the neurology setting ( 2.2 ).
Initiate imaging within 40 minutes following drug injection; acquire static emission images 30-100 minutes from time of injection ( 2 ).
Recommended Dose for
Adults Within the oncology, cardiology and neurology settings, the recommended dose for
adults is 5 to 10 mCi (185 to 370 MBq) as an intravenous injection.
2.2 Recommended Dose for Pediatric Patients Within the neurology setting, the recommended dose for pediatric patients is 2.6 mCi, as an intravenous injection.
The optimal dose adjustment on the basis of body size or weight has not been determined [ see Use in Special Populations (8.4) ].
2.3 Patient Preparation To minimize the radiation absorbed dose to the bladder, encourage adequate hydration.
Encourage the patient to drink water or other fluids (as tolerated) in the 4 hours before their PET study.
Encourage the patient to void as soon as the imaging study is completed and as often as possible thereafter for at least one hour.
Screen patients for clinically significant blood glucose abnormalities by obtaining a history and/or laboratory tests [ see Warnings and Precautions (5.2) ].
Prior to Fludeoxyglucose F 18 PET imaging in the oncology and neurology settings, instruct patient to fast for 4 to 6 hours prior to the drug's injection.
In the cardiology setting, administration of glucose-containing food or liquids (e.g., 50 to 75 grams) prior to Fludeoxyglucose F 18 Injection facilitates localization of cardiac ischemia.
2.4 Radiation Dosimetry The estimated human absorbed radiation doses (rem/mCi) to a newborn (3.4 kg), 1-year old (9.8 kg), 5-year old (19 kg), 10-year old (32 kg), 15-year old (57 kg), and adult (70 kg) from intravenous administration of Fludeoxyglucose F 18 Injection are shown in Table 1.
These estimates were calculated based on human data and using the data published by the International Commission on Radiological Protection for Fludeoxyglucose F 18.
The dosimetry data show that there are slight variations in absorbed radiation dose for various organs in each of the age groups.
These dissimilarities in absorbed radiation dose are due to developmental age variations (e.g., organ size, location, and overall metabolic rate for each age group).
The identified critical organs (in descending order) across all age groups evaluated are the urinary bladder, heart, pancreas, spleen, and lungs.
Table 1:
Estimated Absorbed Radiation Doses (rem/mCi) After Intravenous Administration of Fludeoxyglucose F 18 Injection MIRDOSE 2 software was used to calculate the radiation absorbed dose.
Organ Newborn (3.4 kg) 1-year old (9.8 kg) 5-year old (19 kg) 10-year old (32 kg) 15-year old (57 kg) Adult (70 kg) Bladder wall The dynamic bladder model with a uniform voiding frequency of 1.5 hours was used. 4.3 1.7 0.93 0.60 0.40
0.32 Heart wall 2.4 1.2 0.70 0.44 0.29
0.22 Pancreas 2.2 0.68 0.33 0.25 0.13
0.096 Spleen 2.2 0.84 0.46 0.29 0.19
0.14 Lungs 0.96 0.38 0.20 0.13 0.092
0.064 Kidneys 0.81 0.34 0.19 0.13 0.089
0.074 Ovaries 0.80 0.8 0.19 0.11 0.058
0.053 Uterus 0.79 0.35 0.19 0.12 0.076
0.062 LLI wall LLI = lower large intestine; 0.69 0.28 0.15 0.097 0.060
0.051 Liver 0.69 0.31 0.17 0.11 0.076
0.058 Gallbladder wall 0.69 0.26 0.14 0.093 0.059
0.049 Small intestine 0.68 0.29 0.15 0.096 0.060
0.047 ULI wall ULI = upper large intestine 0.67 0.27 0.15 0.090 0.057
0.046 Stomach wall 0.65 0.27 0.14 0.089 0.057
0.047 Adrenals 0.65 0.28 0.15 0.095 0.061
0.048 Testes 0.64 0.27 0.14 0.085 0.052
0.041 Red marrow 0.62 0.26 0.14 0.089 0.057
0.047 Thymus 0.61 0.26 0.14 0.086 0.056
0.044 Thyroid 0.61 0.26 0.13 0.080 0.049
0.039 Muscle 0. 58 0.25 0.13 0.078 0.049
0.039 Bone surface 0.57 0.24 0.12 0.079 0.052
0.041 Breast 0.54 0.22 0.11 0.068 0.043
0.034 Skin 0.49 0.20 0.10 0.060 0.037
0.030 Brain 0.29 0.13 0.09 0.078 0.072
0.070 Other tissues 0.59 0.25 0.13 0.083 0.052 0.042
2.5 Radiation Safety-Drug Handling Use waterproof gloves, effective radiation shielding, and appropriate safety measures when handling Fludeoxyglucose F 18 Injection to
avoid unnecessary radiation exposure to the patient, occupational workers, clinical personnel and other persons.
Radiopharmaceuticals should be used by or under the control of physicians who are qualified by specific training and experience in the safe use and handling of radionuclides, and whose experience and training have been approved by the appropriate governmental agency authorized to license the use of radionuclides.
Calculate the final dose from the end of synthesis (EOS) time using proper radioactive decay factors.
Assay the final dose in a properly calibrated dose calibrator before administration to the patient [ see Description (11.2) ].
The dose of Fludeoxyglucose F 18 used in a given patient should be minimized consistent with the objectives of the procedure, and the nature of the radiation detection devices employed.
2.6 Drug Preparation and Administration Calculate the necessary volume to administer based on calibration time and dose.
Aseptically withdraw Fludeoxyglucose F 18 Injection from its container.
Inspect Fludeoxyglucose F 18 Injection visually for particulate matter and discoloration before administration, whenever solution and container permit.
Do not administer the drug if it contains particulate matter or discoloration; dispose of these unacceptable or unused preparations in a safe manner, in compliance with applicable regulations.
Use Fludeoxyglucose F 18 Injection within 12 hours from the EOS.
2.7 Imaging Guidelines Initiate imaging within 40 minutes following Fludeoxyglucose F 18 Injection administration.
Acquire static emission images 30 to 100 minutes from the time of injection.

Quoted from the official label, section “Dosage & Administration”.

Other warnings

Radiation risks: use smallest dose necessary for imaging ( 5.1 ).
Blood glucose abnormalities: may cause suboptimal imaging ( 5.2 ).
5.1 Radiation Risks Radiation-emitting products, including Fludeoxyglucose F 18 Injection, may increase the risk for cancer, especially in pediatric patients.
Use
the smallest dose necessary for imaging and ensure safe handling to protect the patient and health care worker [ see Dosage and Administration (2.5) ].
5.2 Blood Glucose Abnormalities In the oncology and neurology setting, suboptimal imaging may occur in patients with inadequately regulated blood glucose levels.
In these patients, consider medical therapy and laboratory testing to assure at least two days of normoglycemia prior to Fludeoxyglucose F 18 Injection administration.

Quoted from the official label, section “Warnings”.

Pregnancy and breastfeeding

Risk Summary Data from published case series and case reports describe Fludeoxyglucose F 18 Injection crossing the placenta with uptake by the fetus (see Data ).
All radiopharmaceuticals have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of the radiation dose.
However, published studies that describe Fludeoxyglucose F 18 Injection use in pregnant women have not identified a risk of drug-associated major birth defects, miscarriage, or adverse maternal or fetal outcomes.
If considering Fludeoxyglucose F 18 Injection administration to a pregnant woman, inform the patient about the potential for adverse pregnancy outcomes based on the radiation dose from Fludeoxyglucose F 18 Injection and the gestational timing of exposure.
The estimated background risk of major birth defects and miscarriage for the indicated population is unknown.
All pregnancies have a background risk of birth defect, loss, or other adverse outcomes.
In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies are 2 to 4% and 15 to 20%, respectively.
Data Human Data Data from published case series and case reports describe Fludeoxyglucose F 18 Injection crossing the placental barrier and visualization of radioactivity throughout the body of the fetus.
The estimated fetal absorbed radiation dose from the maximum labeled dose (370 MBq) of Fludeoxyglucose F 18 was 10 mGy with first trimester exposure to PET alone and 20 mGy with first trimester exposure to PET/CT scan combination.
Long-term adverse radiation effects to a child exposed to Fludeoyxglucose F 18 Injection in utero are unknown.
No adverse fetal effects or radiation-related risks have been identified for diagnostic procedures involving less than 50 mGy, which represents less than 20 mGy fetal doses.
IN SPECIFIC POPULATIONS Lactation: Temporarily discontinue breastfeeding.
A lactating woman should pump and discard breastmilk for 9 hours after Fludeoxyglucose F 18 Injection ( 8.2 ).
Pediatric Use:
Safety and effectiveness in pediatric patients have not been established in the oncology and cardiology settings ( 8.4 ).
8.1 Pregnancy Risk Summary Data from published case series and case reports describe Fludeoxyglucose F 18 Injection crossing the placenta with uptake by the fetus (see Data ).
All radiopharmaceuticals have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of the radiation dose.
However, published studies that describe Fludeoxyglucose F 18 Injection use in pregnant women have not identified a risk of drug-associated major birth defects, miscarriage, or adverse maternal or fetal outcomes.
If considering Fludeoxyglucose F 18 Injection administration to a pregnant woman, inform the patient about the potential for adverse pregnancy outcomes based on the radiation dose from Fludeoxyglucose F 18 Injection and the gestational timing of exposure.
The estimated background risk of major birth defects and miscarriage for the indicated population is unknown.
All pregnancies have a background risk of birth defect, loss, or other adverse outcomes.
In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies are 2 to 4% and 15 to 20%, respectively.
Data Human Data Data from published case series and case reports describe Fludeoxyglucose F 18 Injection crossing the placental barrier and visualization of radioactivity throughout the body of the fetus.
The estimated fetal absorbed radiation dose from the maximum labeled dose (370 MBq) of Fludeoxyglucose F 18 was 10 mGy with first trimester exposure to PET alone and 20 mGy with first trimester exposure to PET/CT scan combination.
Long-term adverse radiation effects to a child exposed to Fludeoyxglucose F 18 Injection in utero are unknown.
No adverse fetal effects or radiation-related risks have been identified for diagnostic procedures involving less than 50 mGy, which represents less than 20 mGy fetal doses.
8.2 Lactation Risk Summary A published case report and case series show the presence of Fludeoxyglucose F 18 Injection in human milk following administration.
There are no data on the effects of Fludeoxyglucose F 18 Injection on the breastfed infant or the effects on milk production.
Exposure of Fludeoxyglucose F 18 Injection to a breastfed infant can be minimized by temporary discontinuation of breastfeeding ( see Clinical Considerations ).
The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Fludeoxyglucose F 18 Injection, any potential adverse effects on the breastfed child from Fludeoxyglucose F 18 Injection or from the underlying maternal condition.
Clinical Considerations To decrease radiation exposure to the breastfed infant, advise a lactating woman to pump and discard breastmilk and
avoid close (breast) contact with the infant for at least 9 hours after the administration of Fludeoxyglucose F 18 Injection.
8.4 Pediatric Use The safety and effectiveness of Fludeoxyglucose F 18 Injection in pediatric patients with epilepsy is established on the basis of studies in adult and pediatric patients.
In pediatric patients with epilepsy, the recommended dose is 2.6 mCi.
The optimal dose adjustment on the basis of body size or weight has not been determined.
In the oncology or cardiology settings, the safety and effectiveness of Fludeoxyglucose F 18 Injection have not been established in pediatric patients.

Quoted from the official label, section “OTC — Pregnancy or Breast Feeding”.

Other medicines

The interaction of Fludeoxyglucose F 18 Injection with other drugs taken by patients undergoing PET imaging has not been studied.

Quoted from the official label, section “Drug Interactions”.

Use in children

The safety and effectiveness of Fludeoxyglucose F 18 Injection in pediatric patients with epilepsy is established on the basis of studies in adult and pediatric patients.
In pediatric patients with epilepsy, the recommended dose is 2.6 mCi.
The optimal dose adjustment on the basis of body size or weight has not been determined.
In the oncology or cardiology settings, the safety and effectiveness of Fludeoxyglucose F 18 Injection have not been established in pediatric patients.

Quoted from the official label, section “Pediatric Use”.

Side effects

Hypersensitivity reactions with pruritus, edema and rash have been reported in the post-marketing setting.
Have emergency resuscitation equipment and personnel immediately available.
Hypersensitivity reactions have occurred; have emergency resuscitation equipment and personnel immediately available ( 6 ).
To report SUSPECTED ADVERSE REACTIONS, contact Barbara Ann Karmanos Cancer Hospital at 313-993-2873 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Quoted from the official label, section “Adverse Reactions”.

What to discuss with your doctor

Instruct patients in procedures that increase renal clearance of radioactivity.
Encourage patients to:
drink water or other fluids (as tolerated) in the 4 hours before their PET study. void as soon as the imaging study is completed and as often as possible thereafter for at least one hour.
Pregnancy Advise pregnant women of the risk of fetal exposure to radiation with Fludeoxyglucose F 18 Injection [ see Use in Specific Populations (8.1) ].
Lactation Advise lactating women that exposure to Fludeoxyglucose F 18 Injection through breast milk can be minimized by pumping and discarding breast milk and avoiding close (breast) contact with the infant for 9 hours after Fludeoxyglucose F 18 Injection [ see Use in Specific Populations (8.2) ].

Quoted from the official label, section “Patient Counseling Information”.

Strengths and forms

FORMS AND STRENGTHS Multiple-dose glass vial containing 0.74 to
11.1 GBq (20 to 300 mCi/mL) of Fludeoxyglucose F 18 Injection and 4.5 mg of sodium chloride in citrate buffer (approximately 22 to 29 mL volume), for intravenous administration.
Multiple-dose glass vial containing 0.74 to
11.1 GBq (20 to 300 mCi/mL) of Fludeoxyglucose F 18 Injection and 4.5 mg of sodium chloride in citrate buffer (approximately 22 to 29 mL volume), for intravenous administration ( 3 ).

Quoted from the official label, section “Dosage Forms & Strengths”.

What it looks like and how it is packed

Fludeoxyglucose F 18 Injection is supplied in a multi-dose, capped 30 mL glass vial containing between 0.74 to
11.1 GBq/mL (20 to 300 mCi/mL), of no carrier added 2-deoxy-2-[F 18]fluoro-D-glucose, at end of synthesis, in approximately 22 to 29 mL.
The contents of each vial are sterile, pyrogen-free and preservative-free.
NDC 78714-001-30 This radiopharmaceutical is licensed by Children's Hospital of Michigan, for distribution to persons licensed pursuant to Michigan's Environmental Regulatory Code, Part XV:
Radiation Protection, as appropriate, or under equivalent licenses of an Agreement State or Licensing State.
Store the Fludeoxyglucose F 18 Injection vial upright in a lead shielded container at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). [see USP Controlled Room Temperature] Store and dispose of Fludeoxyglucose F 18 Injection USP in accordance with the regulations and a general license, or its equivalent, of an Agreement State or a Licensing State.
The expiration date and time are provided on the container label.
Use Fludeoxyglucose F 18 Injection USP within 12 hours from the EOS time.

Quoted from the official label, section “How Supplied”.

How to store it

Store the Fludeoxyglucose F 18 Injection vial upright in a lead shielded container at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). [see USP Controlled Room Temperature] Store and dispose of Fludeoxyglucose F 18 Injection USP in accordance with the regulations and a general license, or its equivalent, of an Agreement State or a Licensing State.
The expiration date and time are provided on the container label.
Use Fludeoxyglucose F 18 Injection USP within 12 hours from the EOS time.

Quoted from the official label, section “Storage and Handling”.

What is in it

11.1 Chemical Characteristics Fludeoxyglucose F 18 Injection is a positron emitting radiopharmaceutical that is used for diagnostic purposes in conjunction with positron emission tomography (PET) imaging.
The active ingredient 2-deoxy-2-[ 18 F]fluoro-D-glucose has the molecular formula of C 6 H 11 18 FO 5 with a molecular weight of 181.26, and has the following chemical structure:
Fludeoxyglucose F 18 Injection is provided as a ready to use sterile, pyrogen free, clear, colorless citrate buffered solution.
Each mL contains between 0.740 to
11.1 GBq (20.0 to 300 mCi) of 2-deoxy-2-[ 18 F]fluoro-D-glucose at the EOS, 4.5 mg of sodium chloride in citrate buffer.
The pH of the solution is between 4.5 and 7.5.
The solution is packaged in a multiple-dose glass vial and does not contain any preservative.
Chemical Structure
11.2 Physical Characteristics Fluorine F 18 has a physical half-life of 109.8 minutes and decays to Oxygen O 18 (stable) by positron decay.
The principal photons useful for imaging are the dual 511 keV "annihilation" gamma photons that are produced and emitted simultaneously in opposite directions when the positron interacts with an electron (Table 2).
Table 2:
Principal Radiation Emission Data for Fluorine F 18 Radiation/Emission %Per Disintegration Mean Energy Positron (β+) 96.73 249.8 keV Gamma (±) Produced by positron annihilation From:
Kocher, D.C.
Radioactive Decay Tables DOE/TIC-I 1026, 89 (1981) 193.46 511.0 keV The specific gamma ray constant (point source air kerma coefficient) for fluorine F 18 is
5.7 R/hr/mCi (1.35 × 10 -6 Gy/hr/kBq) at 1 cm.
The half-value layer (HVL) for the 511 keV photons is 4 mm lead (Pb).
The range of attenuation coefficients for this radionuclide as a function of lead shield thickness is shown in Table 3.
For example, the interposition of an 8 mm thickness of Pb, with a coefficient of attenuation of 0.25, will decrease the external radiation by 75%.
Table 3:
Radiation Attenuation of 511 keV Photons by lead (Pb) shielding Shield thickness (Pb) mm Coefficient of attenuation 0 0.00 4 0.50 8 0.25 13 0.10 26 0.01 39 0.001 52
0.0001 For use in correcting for physical decay of this radionuclide, the fractions remaining at selected intervals after calibration are shown in Table 4.
Table 4:
Physical Decay Chart for Fluorine F 18 Minutes Fraction Remaining 0 calibration time 1.000 15 0.909 30 0.826 60 0.683 110 0.500 220 0.250

Quoted from the official label, section “Description”.

Ingredients people check for

Lactose, gluten, dyes, sugars and other ingredients that matter with an allergy, intolerance or diet — as this product’s FDA label lists them.

The stored label for this product has no list of inactive ingredients. The list on the pack is the one to check.

Quoted from the FDA label. A label that does not name an ingredient is not a guarantee that the product is free of it, and formulations change. With an allergy, check the pack and ask a pharmacist.

Every version of this medicine (8)

The same active substance, strength and kind of form, from every company that sells it — with what each label lists.

Showing 8 of 8

Details

Made by	Barbara Ann Karmanos Cancer Hospital
Active substance	Fludeoxyglucose F-18
Used in	Everything that fits nowhere else, such as contrast media
Strength	300 mCi/mL
Form	Injection
Route	Intravenous
Packs	30 mL in 1 VIAL, GLASS
NDC	78714-001

Source: NDC Directory · 2026-09-13 · not reviewed by a clinician

Source: US Food and Drug Administration, NDC Directory. Reuse terms: US government work (FDA).

Report wrong or outdated information on this page

Other strengths and forms

5 products are sold under this name. Grouped by form; a number on a strength means several companies make it.

Injection3 products
- 300 mCi/mL2
  300 mCi/mL · 2 companies
  - Barbara Ann Karmanos Cancer Hospital · this page
  - BRIGHAM AND WOMEN`S HOSPITAL, INC., THE
- 500 mCi/mL
Injection, Solution2 products
- 200 mCi/mL
- 500 mCi/mL

Same active substance

These contain the same substance. That does not mean one can replace another — ask a pharmacist.

Fludeoxyglucose F 18300 mCi/mLPrescription onlyInjection UIHC-P E T IMAGING CENTER · Fludeoxyglucose F-18 Fludeoxyglucose F 18300 mCi/mLPrescription onlyInjection, Solution Biomedical Research Foundation of Northwest Louisiana · Fludeoxyglucose F-18 Fludeoxyglucose F 1840 mCi/mLPrescription onlyInjection Kettering Medical Center · Fludeoxyglucose F-18 Fludeoxyglucose F 18300 mCi/mLPrescription onlyInjection SOFIE Co. · Fludeoxyglucose F-18 Fludeoxyglucose F 18240 mCi/mLPrescription onlyInjection Mayo Clinic · Fludeoxyglucose F-18 Fludeoxyglucose F 18300 mCi/mLPrescription onlyInjection, Solution Jubilant DraxImage Inc., dba Jubilant Radiopharma · Fludeoxyglucose F-18

See every product with Fludeoxyglucose F-18